CN117398443A - 一种治疗糖尿病肾病的中药组合物及其制备方法 - Google Patents
一种治疗糖尿病肾病的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN117398443A CN117398443A CN202311518509.0A CN202311518509A CN117398443A CN 117398443 A CN117398443 A CN 117398443A CN 202311518509 A CN202311518509 A CN 202311518509A CN 117398443 A CN117398443 A CN 117398443A
- Authority
- CN
- China
- Prior art keywords
- diabetic nephropathy
- parts
- traditional chinese
- chinese medicine
- treating diabetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 80
- 208000007342 Diabetic Nephropathies Diseases 0.000 title claims abstract description 57
- 208000033679 diabetic kidney disease Diseases 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 6
- 229920001353 Dextrin Polymers 0.000 claims abstract description 3
- 239000004375 Dextrin Substances 0.000 claims abstract description 3
- 235000019425 dextrin Nutrition 0.000 claims abstract description 3
- 239000000706 filtrate Substances 0.000 claims abstract description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 3
- 210000000582 semen Anatomy 0.000 claims description 17
- 244000250129 Trigonella foenum graecum Species 0.000 claims description 16
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims description 16
- 235000001019 trigonella foenum-graecum Nutrition 0.000 claims description 16
- 240000007164 Salvia officinalis Species 0.000 claims description 12
- 235000006533 astragalus Nutrition 0.000 claims description 12
- 241000209020 Cornus Species 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 244000046146 Pueraria lobata Species 0.000 claims description 7
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 7
- 241001061264 Astragalus Species 0.000 claims description 6
- 241000045403 Astragalus propinquus Species 0.000 claims description 6
- 210000004233 talus Anatomy 0.000 claims description 6
- 235000005412 red sage Nutrition 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims 2
- 240000007171 Imperata cylindrica Species 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229940023488 pill Drugs 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000006190 sub-lingual tablet Substances 0.000 claims 1
- 229940098466 sublingual tablet Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 36
- 238000011282 treatment Methods 0.000 abstract description 33
- 231100000331 toxic Toxicity 0.000 abstract description 8
- 230000002588 toxic effect Effects 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 5
- 238000001035 drying Methods 0.000 abstract description 3
- 238000001914 filtration Methods 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- 238000002791 soaking Methods 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- 210000002700 urine Anatomy 0.000 description 19
- 241001598107 Imperata Species 0.000 description 14
- 230000007812 deficiency Effects 0.000 description 14
- 206010030113 Oedema Diseases 0.000 description 11
- 244000025254 Cannabis sativa Species 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 235000017276 Salvia Nutrition 0.000 description 7
- 238000012552 review Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 241000759833 Cornus officinalis Species 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000003907 kidney function Effects 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 240000000031 Achyranthes bidentata Species 0.000 description 4
- 239000009636 Huang Qi Substances 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 238000002555 auscultation Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 235000004213 low-fat Nutrition 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 201000001474 proteinuria Diseases 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 208000004611 Abdominal Obesity Diseases 0.000 description 3
- 206010065941 Central obesity Diseases 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 208000037656 Respiratory Sounds Diseases 0.000 description 3
- 208000031975 Yang Deficiency Diseases 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000010349 pulsation Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010013700 Drug hypersensitivity Diseases 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 2
- 206010016946 Food allergy Diseases 0.000 description 2
- 241000288140 Gruiformes Species 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 201000005746 Pituitary adenoma Diseases 0.000 description 2
- 206010061538 Pituitary tumour benign Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 201000005311 drug allergy Diseases 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000037809 hypertension grade 3 Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000021310 pituitary gland adenoma Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 206010037833 rales Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000013600 Diabetic vascular disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000483399 Ipimorpha retusa Species 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241000037831 Polygonatum sibiricum Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 235000016127 added sugars Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 206010004300 benign neoplasm of adrenal gland Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000015210 hypertensive heart disease Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中药组合物技术领域,公开了一种治疗糖尿病肾病的中药组合物及其制备方法,所述治疗糖尿病肾病的中药组合物,由葫芦巴、酒萸肉、黄芪、酒黄精、沙苑子、陈皮、丹参、白茅根、葛根及怀牛膝制成。以上十味,加水煎煮二次,每次1.5小时,第一次加水后浸泡1小时,煎煮液滤过,滤液浓缩至相对密度为1.04~1.09的浓缩液,静置,离心,离心液浓缩至相对密度为1.27~1.32浸膏,干燥,粉碎,加硬脂酸镁及糊精适量,混匀,制成颗粒,即得。本发明提供一种治疗糖尿病肾病更有效、便宜的中药组合物,降低现有药物的毒副作用,提高治疗效果,减轻患者经济负担。
Description
技术领域
本发明属于中药组合物技术领域,尤其涉及一种治疗糖尿病肾病的中药组合物及其制备方法。
背景技术
目前,糖尿病肾病是糖尿病特发性全身微血管病变的肾脏表现,早期表现为尿中排出微量白蛋白,继之出现临床蛋白尿,最后发展为慢性肾功能不全。古代医籍中没有直接对应糖尿病肾病的病名,多归属于中医的“下消”“水肿”“尿浊”“关格”等病范畴,古今多数医家认为本病的形成乃因先天禀赋不足,加之糖毒性、脂毒性,损伤了脏腑的正气,肾为先天之本,肾藏全身之精,肾失封藏,则人体的精微物质外泄,出现蛋白尿。肾主水,肾虚则水液代谢障碍,出现水肿。肾虚则精气下泄,故糖尿病肾病早期主要表现为气阴两虚,气虚尤以肾气虚为著,气虚则无力推动气血运行,血行不畅,导致血瘀、痰湿蕴结。糖尿病肾病久治不愈,后期演变为脾肾两虚、阴阳两虚。此时“阴虚则阳无以附,阳虚则阴无以生”,脾肾两虚,肾精不固,兼湿热、血瘀、湿浊、痰浊等浊邪互结。张景岳《新方八略引》曰:“善补阳者,必于阴中求阳,则阳得阴助而生化无穷;善补阴者,必于阳中求阴,则阴得阳升而泉源不竭。故临床上扶阳固肾,清热养阴的治疗将对糖尿病肾病起重要作用。
通过上述分析,现有技术存在的问题及缺陷为:
糖尿病肾病在中医理论中被归类为多种病症,包括“下消”、“水肿”、“尿浊”、“关格”等。这些理论认为,糖尿病肾病的产生与先天禀赋的不足,以及后天因素(如糖毒性、脂毒性)的损伤有关。在病症的发展过程中,肾脏的功能逐渐衰退,导致蛋白尿、水肿等症状的出现。而且,按照中医理论,肾病的发展还导致气阴两虚、脾肾两虚、阴阳两虚等状态的出现。
1)药物毒副作用大:许多用于治疗糖尿病肾病的药物会对患者的其他器官或系统产生负面影响,导致一系列的副作用。例如,某些药物会导致肠胃不适、肝脏功能受损、皮疹等问题。
2)价格昂贵:用于治疗糖尿病肾病的药物和治疗方法往往价格昂贵,这给患者带来了经济压力。同时,这也给社会医疗保障体系带来了沉重的负担。
基于以上分析,现有技术中急需解决的问题包括:
1)开发副作用小的药物:有必要开发出副作用小、毒性低的新药物,以减轻对患者其他器官或系统的负面影响。
2)降低治疗成本:需要寻找一种能够降低治疗成本的方法,使更多的患者能够负担得起治疗费用,同时减轻社会医疗保障体系的负担。
3)结合中西医治疗:考虑到糖尿病肾病的复杂性,结合中西医理论进行治疗是一种可行的方案。例如,可以在西医的药物治疗基础上,结合中医的扶阳固肾、清热养阴等方法,以期取得更好的治疗效果。
4)早期诊断和预防:糖尿病肾病的早期诊断和预防非常重要。因此,开发更有效的早期检测方法,以及推广健康生活方式和预防措施,对于防止糖尿病肾病的发生和发展具有重要意义。
发明内容
针对现有技术存在的问题,本发明提供了一种治疗糖尿病肾病的中药组合物及其制备方法。
本发明是这样实现的,一种治疗糖尿病肾病的中药组合物,所述治疗糖尿病肾病的中药组合物由葫芦巴、酒萸肉、黄芪、酒黄精、沙苑子、陈皮、丹参、白茅根、葛根及怀牛膝制成;所述中药组合物由如下质量份的中药组分制成:
葫芦巴10-15质量份、酒萸肉10-15质量份、黄芪20-30质量份、酒黄精10-15质量份、沙苑子12-15质量份、陈皮10-12质量份、丹参10-15质量份、白茅根20-30质量份、葛根12-15质量份、怀牛膝10-15质量份。
本发明提供的制法具体为:
以上十味,加水煎煮二次,每次1.5小时,第一次加水后浸泡1小时,煎煮液滤过,滤液浓缩至相对密度为1.04~1.09(60℃)的浓缩液,静置,离心,离心液浓缩至相对密度为1.27~1.32(60℃)浸膏,干燥,粉碎,加硬脂酸镁及糊精适量,混匀,制成颗粒,即得。
结合上述的技术方案和解决的技术问题,本发明所要保护的技术方案所具备的优点及积极效果为:
第一、本发明提供一种治疗糖尿病肾病更有效、便宜的中药组合物,降低现有药物的毒副作用,提高治疗效果,减轻患者经济负担。
本发明与现有技术相比,其组分配比更加简明、科学,全方具有扶阳固肾,清热养阴之功效,方中多采用药食同源类中药,无毒副作用,前期临床观察发现其治疗糖尿病肾病效果佳,安全有效。
第二,作为本发明的权利要求的创造性辅助证据,还体现在以下几个重要方面:
(1)本发明的技术方案转化后的预期收益和商业价值为:
①市场需求:全球糖尿病患者数量呈逐年增长的趋势,对治疗糖尿病肾病的需求也在不断增加,而目前尚缺乏毒副作用小、经济有效的治疗方法。
②独特性和创新性:本发明的中药复合物是基于深入研究糖尿病肾病发病机制的基础上开发而成,具有独特的配方和制备工艺。与传统治疗方法相比,该复合物具有更好的疗效和安全性。
③商业化前景:根据市场需求和独特性,本发明的中药复合物具有良好的商业化前景。一旦获得专利保护,可以通过授权合作或自主生产销售的方式,将该复合物推向市场,从而实现商业化运作和盈利。
(2)本发明的技术方案填补了国内外业内技术空白:
目前,国内外针对糖尿病肾病的治疗方法主要是通过控制血糖、血压等来延缓疾病进展。然而,研究发现这些方法或毒副作用大,或成本高昂,且针对肾功能的进一步恶化疗效有限。本发明的中药复合物采用了特定的中药组合,经过科学的筛选和配比,以最大限度地发挥药物的疗效。这种独特的配方在国内外业内技术中尚未见到类似的应用,填补了该领域的技术空白。
(3)本发明的技术方案解决了人们一直渴望解决、但始终未能获得成功的技术难题:
人们一直在探索中西医结合治疗糖尿病肾病的更为经济、有效、适用人群广的方法,但科学发展无止境,本发明的中药复合物采用来源广泛,成本低的中草药材,经过科学的配比、加工,前期临床试验已证明其疗效好、安全性高,本发明在探索中西医结合治疗糖尿病肾病的路上迈进了一大步,也为未来的基础科研和临床药物研发开辟了新道路。
(4)本发明的技术方案克服了技术偏见:
在治疗糖尿病肾病的领域中,传统的治疗方法主要集中在控制血糖和血压,但这些方法并不能完全阻止肾功能的进一步恶化。因此,一直以来存在着技术偏见,即缺乏有效的治疗方法来改善糖尿病肾病的病理过程。本发明的中药复合物通过独特的配方和治疗机制,针对糖尿病肾病的病理过程进行干预,有效的改善肾功能。与传统治疗方法相比,本发明的技术方案具有明显的优势,能够克服传统治疗方法的局限性和技术偏见,为糖尿病肾病的治疗提供了一种新的选择。
第四,中药组合物优化了配方:通过结合不同的中草药,如葫芦巴、酒萸肉、黄芪、酒黄精、沙苑子、陈皮、丹参、白茅根、葛根和怀牛膝,优化了治疗糖尿病肾病的效果。这些草药有助于改善糖尿病肾病患者的症状,但需要经过科学研究验证。
附图说明
图1是本发明实施例提供的治疗糖尿病肾病的中药组合物的制备方法流程图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
本发明实施例提供的治疗糖尿病肾病的中药组合物,由葫芦巴、酒萸肉、黄芪、酒黄精、沙苑子、陈皮、丹参、白茅根、葛根及怀牛膝制成。
中药组合物包含了多种不同的中药成分,每种成分都有其独特的药理作用。
以下是关于每种成分药理作用的简单介绍:
1.葫芦巴:在中医中,葫芦巴被认为具有降血糖、抗菌、抗炎和抗氧化的作用。
2.酒萸肉:酒萸肉的主要功效是滋阴养血、收敛止汗、安神平肝。
3.黄芪:黄芪被认为具有增强免疫力、抗疲劳和抗衰老的作用。
4.酒黄精:酒黄精被认为具有补脾益气、养血安神的作用。
5.沙苑子:沙苑子被认为具有补肾固精、利水消肿的作用。
6.陈皮:陈皮被认为具有理气健胃、燥湿化痰的作用。
7.丹参:丹参被认为具有活血化瘀、清心除烦的作用。
8.白茅根:白茅根被认为具有利水消肿、清热解毒的作用。
9.葛根:葛根被认为具有发汗解表、清热解毒、生津止渴的作用。
10.怀牛膝:怀牛膝被认为具有疏风活络、强筋骨的作用。
中药组合物的设计目标是针对糖尿病肾病的治疗。糖尿病肾病是糖尿病并发症之一,是由于长期高血糖导致的肾脏疾病。这个中药组合物中的多种成分如葫芦巴、黄芪、丹参等都有助于降低血糖、改善肾功能和提高免疫力。其他的成分如酒萸肉、酒黄精则有助于调节身体的内环境,陈皮、白茅根和葛根有助于改善水肿和排毒,沙苑子和怀牛膝有助于保护肾脏功能。
本发明中糖尿病肾病归属于中医“消渴肾虚劳”范畴,病人处于“正虚邪恋”的状态,已形成阴阳两虚,瘀毒阻络的病机。此时“阴虚则阳无以附,阳虚则阴无以生”,故用葫芦巴与酒萸肉益肾精,补肾阳,两药合用阴阳双补,共为君药。
黄芪健脾补气,为补中益气要药,黄精益气养阴,二药合用可加强益气补脾之功效。沙苑子可补肾精,养肝阴,可增强君药补肾固精之力。三药合用共为臣药。
消渴日久,病邪入络,血脉瘀滞,瘀热互结,浊毒内生。故佐以丹参清热活血,化瘀通络;白茅根清热解毒;陈皮辛香温通,梳理气机,既可化痰祛浊,又能使方中补益药物补而不滞。佐以葛根清扬升散,作用有三,一可配伍黄芪、黄精于清热之中升提脾胃阳气以升清;二可配伍牛膝,宣上导下,升清降浊,使气机调畅,瘀热自除;三能加强酒萸肉滋阴之功。怀牛膝为佐使药,既可佐君药补肝肾,又可通利血脉,引诸药下行入肾,直达病所。
诸药合用,攻补兼施,温而不燥,滋而不腻,标本同治,共奏扶阳固肾,清热养阴,化瘀通络之功。
本发明实施例提供的治疗糖尿病肾病的中药组合物的制备方法为水煎煮法。
本发明提供的中药组合物由如下质量份的中药组分制成:
葫芦巴10-15质量份、酒萸肉10-15质量份、黄芪20-30质量份、酒黄精10-15质量份、沙苑子12-15质量份、陈皮10-12质量份、丹参10-15质量份、白茅根20-30质量份、葛根12-15质量份、怀牛膝10-15质量份。
实施例1:
1.葫芦巴:12重量份
2.酒萸肉:11重量份
3.黄芪:25重量份
4.酒黄精:13重量份5.沙苑子:14重量份6.陈皮:11重量份
7.丹参:14重量份
8.白茅根:25重量份9.葛根:13重量份10.怀牛膝:12重量份实施例2:
1.葫芦巴:10重量份2.酒萸肉:10重量份3.黄芪:20重量份
4.酒黄精:10重量份5.沙苑子:12重量份6.陈皮:10重量份
7.丹参:10重量份
8.白茅根:20重量份9.葛根:12重量份10.怀牛膝:10重量份实施例3:
1.葫芦巴:15重量份2.酒萸肉:15重量份3.黄芪:30重量份
4.酒黄精:15重量份5.沙苑子:15重量份6.陈皮:12重量份
7.丹参:15重量份
8.白茅根:30重量份9.葛根:15重量份10.怀牛膝:15重量份实施例4:
1.葫芦巴:14重量份2.酒萸肉:12重量份3.黄芪:28重量份
4.酒黄精:12重量份5.沙苑子:13重量份6.陈皮:11重量份
7.丹参:11重量份
8.白茅根:22重量份9.葛根:13重量份10.怀牛膝:13重量份实施例5:
1.葫芦巴:13重量份2.酒萸肉:13重量份3.黄芪:23重量份
4.酒黄精:11重量份5.沙苑子:14重量份6.陈皮:10重量份
7.丹参:14重量份
8.白茅根:28重量份
9.葛根:14重量份
10.怀牛膝:14重量份
实施例6:
1.葫芦巴:11重量份
2.酒萸肉:14重量份
3.黄芪:27重量份
4.酒黄精:14重量份
5.沙苑子:12重量份
6.陈皮:10重量份
7.丹参:12重量份
8.白茅根:23重量份
9.葛根:12重量份
10.怀牛膝:11重量份
应用实施例1
患者肖某某,65岁,血糖升高10余年,既往“高血压”病史10余年,“冠心病”4年余,2018年患者因“双肾结石、肌酐升高”行逆行肾路造影及短暂血液透析治疗。否认食物、药物过敏史,否认糖尿病家族史,体检:老年男性,T:36.6℃P:68次/分R:17次/分BP:133/86mmHg身高:175cm体重:94kg,肥胖体型;发育正常,神志清,精神可,双肺呼吸音清,未闻及干湿啰音,心律齐,各瓣膜听诊区未闻及病理性杂音。腹软,无压痛及反跳痛,四肢肌力、肌张力正常,双下肢水肿。
诊断:2型糖尿病性肾病,2型糖尿病性周围神经病,2型糖尿病性周围血管病,2型糖尿病伴多个并发症,2型糖尿病,高血压3级(高危),冠状动脉粥样硬化性心脏病,高血压性心脏病。
治疗:低盐低脂优质蛋白糖尿病饮食,降糖、降压,改善心功能,调脂,营养神经等综合治疗,复方中药护肾。
辅助检查:
治疗前:尿UACR:56.8mg/g
中药1个月后复查:尿UACR:49.23mg/g
中药2个月后复查:尿UACR:39.83mg/g
患者使用中药治疗后尿蛋白明显减少。
应用实施例2
患者侯某某,65岁,发现血糖升高10余年,尿中泡沫2年余。既往高血压病史,否认食物、药物过敏史,否认糖尿病家族史,体检:老年女性,身高155cm,体重55kg,血压145/85mmHg,发育正常,神志清,精神可,双肺呼吸音清,未闻及干湿啰音,心律齐,各瓣膜听诊区未闻及病理性杂音。腹软,无压痛及反跳痛,四肢肌力、肌张力正常,双下肢无水肿。
诊断:2型糖尿病,糖尿病性肾病,高血压
治疗:降糖、降压、改善循环,营养神经等综合治疗,复方中药改善蛋白尿。
辅助检查:
治疗前:UACR:326.92mg/g,
使用中药2个月后复查:尿UACR:168mg/g
使用中药3个月后复查:尿UACR 151.00mg/L
患者使用中药后尿蛋白明显减少。
应用实施例3
患者冷某某。54岁,尿粘6年,既往体健,否认食物、药物过敏史,舅舅、母亲、姨有糖尿病家族,体检:中年男性,腹型肥胖,BP:132/68mmHg,H 175cm,W65 Kg,神志清,甲状腺未触及肿大,双肺呼吸音清,未闻及干湿性啰音,心率69次/分,律齐,各瓣膜听诊区未闻及病理性杂音,腹软,无压痛及反跳痛,肝脾未触及肿大,双下肢无水肿,右下肢,足背动脉搏动弱,腓肠肌压痛。
诊断:2型糖尿病,糖尿病肾病IV期
治疗:低盐低脂糖尿病饮食,降糖、降脂、改善循环等综合治疗,复方中药改善蛋白尿。
辅助检查:
治疗前:尿UACR:151.3mg/g
使用中药1个月后复查:尿UACR:61.3mg/g
使用中药后尿蛋白明显降低。
应用实施例4
患者宋某,46岁,口干、多饮9年,双足麻木5月余,既往“高血压病”史12年余;5年前因垂体腺瘤行内镜下经蝶垂体腺瘤切除术。体检:中年女性,T:36.1℃P:84次/分R:21次/分BP:140/83mmHg身高:166cm体重:92kg,神志清,甲状腺未触及肿大,双肺呼吸音清,未闻及干湿性啰音,心率84次/分,律齐,各瓣膜听诊区未闻及病理性杂音,腹软,腹型肥胖,无压痛及反跳痛,肝脾未触及肿大,双下肢无水肿,足背动脉搏动减弱,双侧膝、跟腱反射正常,四肢末梢浅感觉减退。
诊断:2型糖尿病性肾病(III期),2型糖尿病,高血压病3级(极高危),肾上腺良性肿瘤,脂肪肝
治疗:低盐低脂糖尿病饮食,降糖,降压,降尿酸、营养神经等综合治疗,复方中药改善蛋白尿。
辅助检查:
治疗前:尿UACR 116.30mg/g。
使用中药1个月后复查:尿UACR 70.71mg/g。
使用中药后,尿蛋白明显降低。
应用实施例5
患者宁某某,68岁男性,因“口干、多饮3年,尿中泡沫增多3月”入院,既往高血压病史10年,40年前确诊肺结核,自诉已治愈。查体:腹型肥胖,心肺腹查体未见阳性体征,双侧足背动脉搏动减弱,左足触觉粗测减弱。
诊断:2型糖尿病性肾病Ⅳ期2型糖尿病伴多个并发症高血压病2级(极高危)高脂血症
治疗:低盐低脂糖尿病饮食,降糖、降脂、降尿酸、营养神经、改善循环等综合治疗,复方中药改善蛋白尿。
辅助检查:
治疗前:UACR 302.92mg/g,
使用中药1月后复查:UACR 289.10mg/g。
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,都应涵盖在本发明的保护范围之内。
Claims (10)
1.一种治疗糖尿病肾病的中药组合物,其特征在于,所述治疗糖尿病肾病的中药组合物由葫芦巴、酒萸肉、黄芪、酒黄精、沙苑子、陈皮、丹参、白茅根、葛根及怀牛膝制成。
2.如权利要求1所述的所述中药组合物其特征在于,由如下质量份的中药组分制成:
葫芦巴10-15质量份、酒萸肉10-15质量份、黄芪20-30质量份、酒黄精10-15质量份、沙苑子12-15质量份、陈皮10-12质量份、丹参10-15质量份、白茅根20-30质量份、葛根12-15质量份、怀牛膝10-15质量份。
3.一种如权利要求1所述治疗糖尿病肾病的中药组合物的制备方法,其特征在于,以上十味,加水煎煮二次,每次1.5小时,第一次加水后浸泡1小时,煎煮液滤过,滤液浓缩至相对密度为1.04~1.09的浓缩液,静置,离心,离心液浓缩至相对密度为1.27~1.32浸膏,干燥,粉碎,加硬脂酸镁及糊精适量,混匀,制成颗粒,即得。
4.一种包含权利要求1所述治疗糖尿病肾病的中药组合物的治疗糖尿病肾病的颗粒剂。
5.一种包含权利要求1所述治疗糖尿病肾病的中药组合物的治疗糖尿病肾病的气雾剂。
6.一种包含权利要求1所述治疗糖尿病肾病的中药组合物的治疗糖尿病肾病的丸剂。
7.一种包含权利要求1所述治疗糖尿病肾病的中药组合物的治疗糖尿病肾病的散剂。
8.一种包含权利要求1所述治疗糖尿病肾病的中药组合物的治疗糖尿病肾病的膏剂。
9.一种包含权利要求1所述治疗糖尿病肾病的中药组合物的治疗糖尿病肾病的汤剂。
10.一种包含权利要求1所述治疗糖尿病肾病的中药组合物的治疗糖尿病肾病的舌下片。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311518509.0A CN117398443A (zh) | 2023-11-15 | 2023-11-15 | 一种治疗糖尿病肾病的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311518509.0A CN117398443A (zh) | 2023-11-15 | 2023-11-15 | 一种治疗糖尿病肾病的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117398443A true CN117398443A (zh) | 2024-01-16 |
Family
ID=89497966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311518509.0A Pending CN117398443A (zh) | 2023-11-15 | 2023-11-15 | 一种治疗糖尿病肾病的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117398443A (zh) |
-
2023
- 2023-11-15 CN CN202311518509.0A patent/CN117398443A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111729064A (zh) | 一种健脾通阳中药组合物及其应用 | |
CN104013849A (zh) | 一种治疗高血压病的中药组合物及其制备方法 | |
CN103202879B (zh) | 一种治疗慢性心力衰竭的中药组合物及制备方法 | |
CN101972353A (zh) | 一种用于防治心脑血管疾病的药物组合物 | |
CN101095768B (zh) | 一种治疗中老年原发性高血压的中药胶囊 | |
CN105250890A (zh) | 一种治疗高脂血症中药 | |
CN102198228A (zh) | 治疗高血压的中药制剂 | |
CN101190294A (zh) | 治疗痛风病的中药 | |
CN103301355A (zh) | 一种慢性肾衰竭结肠透析液制备方法 | |
CN1179034C (zh) | 一种保健药酒 | |
CN100488558C (zh) | 一种治疗心脏病的药物及制备方法 | |
CN117398443A (zh) | 一种治疗糖尿病肾病的中药组合物及其制备方法 | |
CN101249176B (zh) | 蒸泡脚部的中药组合物 | |
CN1399999A (zh) | 一种治疗恶性肿瘤病的药物及其制备方法 | |
CN102908425A (zh) | 一种治疗心脏病及血脂稠的药物及其制备方法 | |
CN1098701C (zh) | 一种治疗心脑血管疾病的药物 | |
CN103028076B (zh) | 一种治疗肝硬化的中药组合物 | |
CN102357172B (zh) | 一种治疗早期慢性肾功能不全的中药组合物 | |
CN105194355A (zh) | 一种治疗原发性高血压的中药制剂 | |
CN111000969A (zh) | 一种治疗单纯性肥胖的药物组合物及制备方法 | |
CN104258351A (zh) | 一种治疗酒精性心肌病的中药制剂及其制备方法 | |
CN108066735A (zh) | 一种治疗慢性肾炎的中药组合物 | |
CN103055159B (zh) | 一种治疗高血压的药物 | |
CN108498622A (zh) | 一种治疗冠心病的中药组合物 | |
CN118593658A (zh) | 一种治疗肝郁脾虚型代谢相关脂肪性肝病的中药组合物、制剂与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |